Ignite Creation Date:
2024-07-17 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475586
Status:
COMPLETED
Last Update Posted:
2024-07-01
First Post:
2024-06-11
Brief Title:
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
Sponsor:
University of Banja Luka
Organization:
University of Banja Luka
Study Overview
Official Title:
Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response
Detailed Description:
After being informed about the study and potential risiks all patients giving written informed consent will undergo a 1-week screening period to determine eliglibility for study entry at week 0 patients who meet the eligibility requirements will be randomized
Study was conducted in two cohort Cohort 1 Patients with DMT2 and psoriasis who are already on metformin therapy in the maximally tolerated dose and to whom semaglutide will be introduced into the therapy in the maximum tolerated dose of semaglutide 025mg 05mg per week or 10mg per week
Cohort 2 Patients with DMT2 and psoriasis who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics except on therapy with GLP-1 RA and SGLT-2 inhibitors
Study was conducted in two cohort Cohort 1 Patients with DMT2 and psoriasis who are already on metformin therapy in the maximally tolerated dose and to whom semaglutide will be introduced into the therapy in the maximum tolerated dose of semaglutide 025mg 05mg per week or 10mg per week
Cohort 2 Patients with DMT2 and psoriasis who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics except on therapy with GLP-1 RA and SGLT-2 inhibitors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None